← feed

Is NCT02223247 results overdue?

Yes — results are overdue. Primary completion was 2017-06; the FDAAA-801 reporting deadline (2018-06-30) passed 2913 days ago and no results are posted on ClinicalTrials.gov.

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

NCT IDNCT02223247 ↗
SponsorSagimet Biosciences Inc. (INDUSTRY)
Public issuerSagimet Biosciences Inc. — SGMT (CIK 0001400118) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-06 (ACTUAL)
Reporting deadline2018-06-30 (completion + 365d)
Days overdue2913
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 916ee7c1433ecc2e… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02223247. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →